Article
Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial.
Nature medicine - 1 Dec 2020
Burd Amy, Levine Ross L, Ruppert Amy S, Mims Alice S, Borate Uma, Stein Eytan M, Patel Prapti, Baer Maria R, Stock Wendy, Deininger Michael, Blum William, Schiller Gary, Olin Rebecca, Litzow Mark, Foran James, Lin Tara L, Ball Brian, Boyiadzis Michael, Traer Elie, Odenike Olatoyosi, Arellano Martha, Walker Alison, Duong Vu H, Kovacsovics Tibor, Collins Robert, Shoben Abigail B, Heerema Nyla A, Foster Matthew C, Vergilio Jo-Anne, Brennan Tim, Vietz Christine, Severson Eric, Miller Molly, Rosenberg Leonard, Marcus Sonja, Yocum Ashley, Chen Timothy, Stefanos Mona, Druker Brian, Byrd John C
Abstract excerpt
Acute myeloid leukemia (AML) is the most common diagnosed leukemia. In older adults, AML confers an adverse outcome1,2. AML originates from a dominant mutation, then acquires collaborative transformative mutations leading to myeloid transformation and clinical/biological heterogeneity. Currently, AML treatment is initiated rapidly, precluding the ability to consider the mutational profile of a patient's leukemia...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.